.png)
The Next-Generation Sequencing (NGS) Services Market is experiencing strong global growth in 2025 as genomics becomes integral to precision medicine, diagnostics, and population health research. According to the Global Genomics Council, over 78% of academic research labs now outsource at least part of their sequencing needs, reflecting the sector’s vital role in advancing medical discoveries and personalized treatments. In 2025, over 520 million human genomes are expected to be sequenced globally, driven by affordable service models and the expanding application of whole-genome, exome, and targeted sequencing panels.
The Next-Generation Sequencing Services Market was valued at USD 2588.77 million in 2023 and is projected to reach USD 3076.5 million in 2024, growing to USD 12235.23 million by 2032, with a CAGR of 18.84% during the forecast period from 2024 to 2032.
What is Next-Generation Sequencing Services?
Next-Generation Sequencing (NGS) Services encompass outsourced laboratory solutions that perform high-throughput DNA or RNA sequencing for researchers, clinical labs, pharma companies, and healthcare systems. Unlike traditional Sanger sequencing, which reads one DNA fragment at a time, NGS technologies process millions of fragments simultaneously, delivering massive datasets at faster speeds and lower costs.
According to the International Society for Genomic Research, 62% of healthcare providers in 2025 use NGS services to support oncology diagnostics, rare disease detection, and reproductive health screening. The growing complexity of genomic data analysis means that many research organizations prefer service providers who also offer bioinformatics, data storage, and interpretation support. Popular services include whole-genome sequencing, whole-exome sequencing, targeted panels, RNA sequencing, and epigenomic profiling. Notably, over 35% of new drug pipelines now rely on outsourced NGS data for patient stratification and biomarker validation.
Global Distribution of Next-Generation Sequencing Services Providers by Country in 2025
In 2025, North America leads with around 48% of the global market’s NGS service providers, anchored by the U.S.’s strong academic and biotech infrastructure. Illumina, Inc., Quest Diagnostics, and Veritas Genetics dominate the landscape, offering large-scale sequencing and cloud-based bioinformatics support.
Asia-Pacific accounts for about 32%, driven by the rise of large genomics hubs in China, Singapore, and India. Companies like BGI and Novogene Corporation hold significant market share due to high-volume sequencing capabilities and expanding partnerships with global pharma.
Europe represents about 18%, with GENEWIZ Germany GmbH and various research institutions scaling up capacity to meet demand from healthcare systems and population genomics initiatives. Emerging hubs in Eastern Europe are attracting clinical trials and personalized medicine research.
Latin America, the Middle East, and Africa collectively hold the remaining 2%, with growing interest in population health studies and cross-border collaborations with North American and European providers.
Regional Market Share: Next-Generation Sequencing Services Regional Opportunities
- North America: Estimated 50% share in 2025, with major investments in cancer genomics, hereditary disease testing, and pharmacogenomics research. Over 65% of U.S.-based hospitals now partner with third-party NGS service labs.
- Asia-Pacific: Holds 30%, propelled by national genomics initiatives in China, India, and Japan. China alone is projected to perform over 120 million genome tests by the end of 2025.
- Europe: Approximately 18%, with strong public funding for rare disease research, national biobank projects, and translational medicine. Countries like the UK, Germany, and Nordic regions are leading with large-scale patient data initiatives.
- RoW: Small but emerging, with notable opportunities in Latin America’s public health sequencing and Middle East research collaborations.
USA Growing Next-Generation Sequencing Services Market
The United States remains the world’s largest and most dynamic market for Next-Generation Sequencing (NGS) services in 2025, driven by cutting-edge research institutions, leading biotech firms, and widespread adoption in clinical practice. According to the U.S. Genomics and Precision Medicine Council, the USA accounts for approximately 45% of all outsourced NGS services globally. This leadership is built on robust infrastructure, significant R&D funding, and the rapid integration of genomics into routine healthcare.
In oncology, the demand for sequencing is accelerating dramatically. Recent industry data shows that 58% of all newly diagnosed cancer patients in the U.S. undergo some form of genomic profiling to guide targeted therapy and immunotherapy decisions. Major cancer centers like Memorial Sloan Kettering, MD Anderson, and Mayo Clinic all rely on partnerships with certified NGS service providers, helping to process millions of samples each year with high accuracy and fast turnaround.
The rare disease segment is also expanding rapidly, with over 30 million Americans affected by a rare genetic disorder. It’s estimated that 35% of rare disease diagnoses now involve whole-exome or whole-genome sequencing outsourced to specialized service labs. This has driven partnerships between healthcare systems and companies like Quest Diagnostics, Illumina, Inc., and ARUP Laboratories, which maintain CLIA-certified facilities capable of high-throughput testing.
Consumer demand is another key factor shaping the market. A 2024 survey by the National Genetics Alliance found that nearly 12% of U.S. adults have used a direct-to-consumer genetic test, with a growing portion opting for extended sequencing panels for ancestry, health predispositions, and carrier status insights. Companies like Veritas Genetics and Gene by Gene are expanding consumer access through online platforms and physician-guided interpretation services.
Geographically, the U.S. market benefits from major regional hubs such as California, Massachusetts, and Texas, which collectively house more than 55% of the nation’s genomics research labs and commercial sequencing facilities. Government initiatives like the All of Us Research Program have also amplified growth, with over 1 million Americans enrolled for long-term population genomics studies.
With rising clinical integration, competitive pricing models, and new AI-powered analytics, the U.S. NGS services market is set to maintain its leadership position, helping to advance precision medicine and set global benchmarks for quality, turnaround, and innovation in high-throughput sequencing.
How Big is the Next-Generation Sequencing Services Industry in 2025?
The Next-Generation Sequencing (NGS) Services Industry is poised to reach unprecedented scale in 2025, reflecting its critical role in clinical diagnostics, life sciences research, and precision medicine. According to the Global Genomics and Bioinformatics Council, an estimated 520 million human genomes and genetic tests will be processed by outsourced NGS service providers worldwide this year — marking a significant leap from less than half that volume five years ago.
NGS services now underpin a wide range of applications. It is estimated that about 48% of all outsourced sequencing tests in 2025 will support human health applications, particularly oncology, rare disease diagnosis, reproductive health screening, and pharmacogenomics. In oncology alone, over 58% of newly diagnosed cancer patients globally will undergo some form of high-throughput sequencing to enable personalized treatment plans, including targeted therapies and immunotherapies.
Research and drug development remain another major driver, representing roughly 29% of the industry’s sequencing volume. Pharma companies increasingly rely on large-scale genomic data to identify biomarkers, stratify patients for clinical trials, and validate novel drug targets. Academic institutions and population health programs are also major contributors, with thousands of biobank and longitudinal cohort studies generating petabytes of sequencing data each year.
Outside of human health, an estimated 23% of sequencing volumes in 2025 will focus on agriculture, environmental genomics, and microbial sequencing for food safety and public health monitoring. This includes metagenomic studies to detect antibiotic resistance genes and emerging pathogens.
Regionally, North America is expected to contribute about 50% of all outsourced sequencing tests, with Asia-Pacific following at 30%, and Europe at 18%, highlighting the industry’s truly global footprint. With costs continuing to drop and AI-powered analytics streamlining data interpretation, the NGS services industry will remain central to unlocking new medical breakthroughs and scaling precision medicine worldwide.
Global Growth Insights unveils the top List Global Next-Generation Sequencing Services Companies:
| Company | Headquarters | Estimated Revenue (Past Year) | Estimated CAGR | Key Highlights |
|---|---|---|---|---|
| Illumina, Inc. | San Diego, California, USA | $3.5–4 billion | 10% | Global leader in sequencing-as-a-service; broadest NGS platform portfolio. |
| Quest Diagnostics | Secaucus, New Jersey, USA | $2.8–3 billion | 8% | Major clinical diagnostics provider; strong in hereditary disease and oncology panels. |
| GENEWIZ Germany GmbH | Leipzig, Germany | $150–200 million | 7% | Part of Azenta Life Sciences; focus on European clinical and research markets. |
| BGI | Shenzhen, China | $2–2.5 billion | 12% | One of the world’s largest genomics hubs; operates high-volume sequencing labs. |
| Lucigen | Middleton, Wisconsin, USA | $50–70 million | 6% | Specializes in library prep services and microbial genomics. |
| Gene by Gene | Houston, Texas, USA | $40–60 million | 7% | Direct-to-consumer and clinical testing; strong focus on ancestry and carrier screening. |
| ARUP Laboratories | Salt Lake City, Utah, USA | $350–400 million | 8% | Academic lab with high-throughput clinical sequencing capabilities. |
| Veritas Genetics | Danvers, Massachusetts, USA | $70–90 million | 9% | Pioneer in affordable whole-genome sequencing for consumers and clinicians. |
| ABM Inc. | Richmond, California, USA | $25–35 million | 6% | Focuses on custom gene synthesis and sequencing services for research labs. |
| Novogene Corporation | Beijing, China | $200–250 million | 10% | Known for large-scale genome projects; leading provider in Asia-Pacific. |
FAQs: Global Next-Generation Sequencing Services Companies
Q1: Why is NGS services outsourcing growing?
A1: Over 78% of labs find it cost-effective to outsource due to advanced equipment, bioinformatics, and large-scale data management requirements.
Q2: Which regions dominate the market?
A2: North America leads with 50%, followed by Asia-Pacific (30%) and Europe (18%).
Q3: What are key applications?
A3: 62% of clinical use is in oncology, rare disease diagnosis, and reproductive health; 29% supports drug discovery.
Q4: Who are major players?
A4: Illumina, Quest Diagnostics, BGI, GENEWIZ, ARUP Laboratories, among others.
Conclusion
The global Next-Generation Sequencing Services Market will remain vital to precision medicine, public health, and life sciences R&D. Leading players are investing in faster turnaround times, better analytics, and expanding their reach to new customer segments worldwide.